The beneficial effects of NOB against decompensated cardiac hypertrophy were also reversed by the PPARγ inhibitor, as indicated by the enhanced ANP and BNP expression assessed by qRT-PCR (Figure 7(d)) and the enlarged cross-sectional area of cardiomyocytes revealed by HE and WGA staining (Figure 7(e)). The gene discussed is NPPA; the disease is cardiac hypertrophy.